Vizgen Unveils MERSCOPE Protein Co-detection Kit Enabling Simultaneous Imaging of Transcripts and Proteins in a Single Experiment

Vizgen Unveils MERSCOPE Protein Co-detection Kit Enabling Simultaneous Imaging of Transcripts and Proteins in a Single Experiment

CAMBRIDGE, Mass. – September 20, 2022— Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the launch of the Protein Co-detection Kit for the MERSCOPE® Platform, enabling subcellular spatial multi-omics measurement with the simultaneous detection of RNA and proteins during a standard MERFISH experiment.

“The release of this kit underscores Vizgen’s growing momentum and commitment to our product roadmap, allowing for simultaneous RNA and protein detection in one run while offering the flexibility for users to continue working with their primary antibodies,” said Terry Lo, President and CEO of Vizgen. “We are excited to provide the scientific community with access to subcellular spatial multi-omics measurements, and to continue developing tools that have the potential to benefit human health.”

While RNA imaging can resolve the gene expression at a single cell level and help annotate the cell state in complex tissue, information such as cell morphology and pathological features can only be imaged by proteins. The MERSCOPE Protein Stain Reagent Kit offers high quality protein staining, equivalent to that of protein immunofluorescence staining, and its oligo conjugated antibodies enable heightened detection of primary antibodies targeting proteins. With the ability to help reveal how different RNA transcripts are localized in intracellular organelles, the kit enables next-level transcript staining with its MERFISH technology, and provides multiplexed, error robust, transcript detection, and an impressive correlation with bulk RNA-seq data for high, medium and low expressing genes.

“Mapping complex proteins and genomic interactions at the cellular, intracellular and subcellular levels is fundamental to understanding human disease and health, and the need for technologies that enable scientists to track these interactions is urgent,”said David Walt, professor of pathology at Harvard Medical School, Core Faculty member of the Wyss Institute and Co-founder and member of Scientific Advisory Board of Vizgen.

Please visit the product page for additional information: https://info.vizgen.com/protein-detection

About Vizgen

Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics, setting the standard for the spatial genomics field. These tools are enabling researchers to gain new insight into the biological systems that govern human health and disease with spatial context. The company’s MERSCOPE® Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development. For more information, go to www.vizgen.com. For more information, go to www.vizgen.com. Connect on social media Twitter, LinkedIn and Facebook.



Holly Hancock
MacDougall Advisors


Brittany Auclair